The changes and resultant impacts on product approval timelines and interactions for life science companies with the FDA continues to be one of the key factors occupying the minds of those leading and advising companies on their navigation of their product development and value creation journeys. Following a successful One Nucleus breakfast seminar hosted by Orrick during BIO in Boston, we are delighted to be working with Georgia Ravitz and colleagues again for an update on the changes at the FDA and how recent changes are settling in.

Agenda:
16.00 – Welcome
16.05 – Keynote Presentation, Georgia Ravitz, Partner at Orrick | FDA & Healthcare Regulation
16.30 – Q&A
16.55 – Closing Remarks
17.00 – Close
 
Registration:
This webinar is free to attend and open to all.